Moderna will seek National Immunisation Program listings for two mRNA vaccines at the Pharmaceutical Benefits Advisory Committee's March 2027 meeting. The agenda includes 31 major submissions and resubmissions, 8 minor submissions, and 4 utilisation reviews. Consumer comments close on 20 January 2027.
Moderna's mRNA flu vaccines and a GLP-1 review headline March PBAC agenda
November 19, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
Government turns again to cheaper medicines as Guild eyes co-payment freeze
November 19, 2026 - - Latest News -
New Zealand risks losing $763 million clinical trials sector as other countries step up
November 19, 2026 - -
A tale of two government programs - one held flat and the other still running hot
November 19, 2026 - - Latest News -
Moderna's mRNA flu vaccines and a GLP-1 review headline March PBAC agenda
November 19, 2026 - - Latest News -
Immutep goes back to smaller batch efti after review finds glycan differences in failed trial drug
November 18, 2026 - - Australian Biotech -
Genetic Signatures walks away from Microba merger after funding shortfall
November 18, 2026 - - Australian Biotech -
Hungary's Gedeon Richter offers $604 million for Mayne Pharma
November 18, 2026 - - Latest News

